


# Author's Accepted Manuscript

Transient hair loss during treatment with dimethyl-fumarate for Multiple Sclerosis

Francesco Antonio Losavio, Matteo Lucchini, Chiara De Fino, Massimiliano Mirabella, Viviana Nociti



PII: S2211-0348(16)30025-6  
DOI: <http://dx.doi.org/10.1016/j.msard.2016.03.006>  
Reference: MSARD371

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 1 November 2015  
Revised date: 1 March 2016  
Accepted date: 14 March 2016

Cite this article as: Francesco Antonio Losavio, Matteo Lucchini, Chiara De Fino, Massimiliano Mirabella and Viviana Nociti, Transient hair loss during treatment with dimethyl-fumarate for Multiple Sclerosis, *Multiple Sclerosis and Related Disorders*, <http://dx.doi.org/10.1016/j.msard.2016.03.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain

**Transient hair loss during treatment with dimethyl-fumarate for Multiple Sclerosis**

Francesco Antonio Losavio<sup>1</sup>, Matteo Lucchini<sup>1</sup>, Chiara De Fino<sup>1</sup>, Massimiliano Mirabella<sup>1</sup>, Viviana Nociti<sup>1,2</sup>

<sup>1</sup>Institute of Neurology, Department of Geriatrics, Neurosciences and Orthopedics, Catholic University, Rome, Italy

<sup>2</sup>Don Carlo Gnocchi Foundation, Italy

**Correspondence to:** Viviana Nociti, MD, PhD, Institute of Neurology, Department of Geriatrics, Neurosciences and Orthopedics, Catholic University, Largo A. Gemelli 8, 00168 Rome, Italy, Tel:+390630154335 fax:+390635501909, email: viviana.nociti@policlinicogemelli.it

Abstract

**Introduction**

Dimethyl-fumarate is a recently approved drug for relapsing-remitting Multiple Sclerosis in Italy.

**Clinical Case**

A 55-year-old woman started therapy with dimethyl-fumarate on June 2014; it was well-tolerated aside from moderate flushing. Starting September 2014 she noticed a progressive hair loss, that neither the dermatological examination nor clinical and medical history nor blood investigations could explain. The hair loss slowed down after two months and was followed by a hair growth back.

**Discussion**

Transient hair loss is not a reported side effect of dimethyl-fumarate therapy but by excluding any known cause we attributed it to the beginning of the new therapy.

**Keywords:** Multiple sclerosis, Disease modifying therapies, Side Effect, Hair Loss, Dimethyl-fumarate.

**Introduction**

Dimethyl-fumarate (Tecfidera®) is a second-generation fumaric acid compound that contains only dimethylester fumarate. Both of the phase III trials showed that Tecfidera® exhibited good safety and tolerability profiles.<sup>1,2</sup> Adverse events that occurred significantly more often in treated patients included gastrointestinal symptoms (specifically, upper abdominal pain, diarrhea, and nausea) and hot flushes, which typically commenced within 30 min of drug administration and subsided within 90 min.

**Clinical Case**

A 55-year-old woman affected by relapsing-remitting Multiple Sclerosis (RR-MS) diagnosed in 1990 with

Download English Version:

<https://daneshyari.com/en/article/5912185>

Download Persian Version:

<https://daneshyari.com/article/5912185>

[Daneshyari.com](https://daneshyari.com)